<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27111533</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>06</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>01</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1528-1175</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>125</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2016</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Anesthesiology</Title>
<ISOAbbreviation>Anesthesiology</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of Dexmedetomidine on Intestinal Microcirculation and Intestinal Epithelial Barrier in Endotoxemic Rats.</ArticleTitle>
<Pagination>
<MedlinePgn>355-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/ALN.0000000000001135</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND">Dexmedetomidine reduces cytokine production in septic patients and reduces inflammation and mortality in experimental models of endotoxemia and sepsis. This study investigated whether dexmedetomidine attenuates endothelial dysfunction, intestinal microcirculatory dysfunction, and intestinal epithelial barrier disruption in endotoxemic rats.</AbstractText>
<AbstractText Label="METHODS">Ninety-two male Wistar rats were randomly assigned to the following four groups: (1) Sham; (2) lipopolysaccharide, received IV lipopolysaccharide 15 and 10 mg/kg at 0 and 120 min; (3) dexmedetomidine, received IV dexmedetomidine for 240 min; and (4) lipopolysaccharide + dexmedetomidine, received both lipopolysaccharide and dexmedetomidine. Sidestream dark-field videomicroscope, tissue oxygen monitor, and full-field laser perfusion image were used to investigate the microcirculation of the terminal ileum. Serum endocan level was measured. The Ussing chamber permeability assay, lumen-to-blood gadodiamide passage by magnetic resonance imaging, and bacterial translocation were conducted to determine epithelial barrier function. Mucosal apoptotic levels and tight junctional integrity were also examined.</AbstractText>
<AbstractText Label="RESULTS">The density of perfused small vessels in mucosa, serosal muscular layer, and Peyer patch in the lipopolysaccharide + dexmedetomidine group was higher than that of the lipopolysaccharide group. Serum endocan level was lower in the lipopolysaccharide + dexmedetomidine group than in the lipopolysaccharide group. Mucosal ratio of cleaved to full-length occludin and spleen bacterial counts were significantly lower in the lipopolysaccharide + dexmedetomidine group than in the lipopolysaccharide group.</AbstractText>
<AbstractText Label="CONCLUSION">The study finding suggests that dexmedetomidine protects against intestinal epithelial barrier disruption in endotoxemic rats by attenuating intestinal microcirculatory dysfunction and reducing mucosal cell death and tight junctional damage. (Anesthesiology 2016; 125:355-67).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yeh</LastName>
<ForeName>Yu-Chang</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>From the Department of Anesthesiology, National Taiwan University Hospital (Y.-C.Y., C.-Y.W., Y.-J.C., C.-M.L., Z.-G.W., W.-Z.S.) and the Graduate Institutes of Physiology, College of Medicine (L.C.-H.Y.), National Taiwan University, Taipei, Taiwan, Republic of China; Department of Medical Imaging, Taipei Buddhist Tzu Chi General Hospital, New Taipei, Taiwan, Republic of China (J.-K.H.); and Department of Anesthesiology, Far Eastern Memorial Hospital, New Taipei, Taiwan, Republic of China (W.-S.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Chun-Yu</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>Ya-Jung</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Chih-Min</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hsiao</LastName>
<ForeName>Jong-Kai</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Wing-Sum</ForeName>
<Initials>WS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Zong-Gin</ForeName>
<Initials>ZG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Linda Chia-Hui</ForeName>
<Initials>LC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Wei-Zen</ForeName>
<Initials>WZ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Anesthesiology</MedlineTA>
<NlmUniqueID>1300217</NlmUniqueID>
<ISSNLinking>0003-3022</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>67VB76HONO</RegistryNumber>
<NameOfSubstance UI="D020927">Dexmedetomidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018988">Bacterial Translocation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020927">Dexmedetomidine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019446">Endotoxemia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006993">Hypnotics and Sedatives</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007422">Intestines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008833">Microcirculation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010101">Oxygen Consumption</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010539">Permeability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012039">Regional Blood Flow</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019108">Tight Junctions</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27111533</ArticleId>
<ArticleId IdType="doi">10.1097/ALN.0000000000001135</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>